Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Authors
Keywords
-
Journal
npj Precision Oncology
Volume 6, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-01
DOI
10.1038/s41698-022-00256-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN
- (2020) Keith T Flaherty et al. JNCI-Journal of the National Cancer Institute
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
- (2020) Keith T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Characterization of Thyroid Cancer Driven by Known and Novel ALK Fusions
- (2019) Federica Panebianco et al. ENDOCRINE-RELATED CANCER
- Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
- (2019) Alice T Shaw et al. LANCET ONCOLOGY
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
- (2019) Alexander Drilon et al. LANCET ONCOLOGY
- Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
- (2018) Patrick Schöffski et al. Lancet Respiratory Medicine
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study
- (2017) Yael P. Mossé et al. JOURNAL OF CLINICAL ONCOLOGY
- Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial
- (2017) Chih-Jian Lih et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- ChromoplecticTPM3–ALKrearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
- (2016) A. S. Mansfield et al. ANNALS OF ONCOLOGY
- Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy
- (2014) Giuseppe Bronte et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
- (2014) Thomas Wiesner et al. Nature Communications
- Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
- (2014) C. M. Lovly et al. Cancer Discovery
- Identification ofROS1rearrangement in gastric adenocarcinoma
- (2013) Jeeyun Lee et al. CANCER
- Molecular Pathways: ROS1 Fusion Proteins in Cancer
- (2013) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer
- (2013) B Solomon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- (2013) Yael P Mossé et al. LANCET ONCOLOGY
- Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia
- (2013) Daniela Cilloni et al. LEUKEMIA RESEARCH
- Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
- (2012) Hiroyuki Yasuda et al. Journal of Thoracic Oncology
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
- (2010) T. Sasaki et al. CANCER RESEARCH
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
- (2010) Benjamin Solomon et al. Journal of Thoracic Oncology
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
- (2010) James E. Butrynski et al. NEW ENGLAND JOURNAL OF MEDICINE
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
- (2008) Y. L. Choi et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now